Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AssigneeDePuy Synthes Products, Inc.
InventorsThomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Melissa Grace, Michael Slivka, Thomas G. Ferro, Vivek N. Shenoy, Alonzo D. Cook, Scott Bruder
Life of this patent
Estimating the term…
Abstract
This invention relates to local administration of a bone-forming agent and at least one anti-resorptive agent to treat osteoporosis and related disorders.
Claims23
A method of therapeutically treating an uncoupled resorbing bone in a patient, comprising the steps of:
- a) administering an effective amount of a first formulation comprising a bone forming agent into the cancellous or cortical portion of the uncoupled resorbing bone, and
- b) administering an effective amount of a second formulation comprising an anti-resorptive agent in a sustained release form into the cancellous or cortical portion of the uncoupled resorbing bone, wherein the anti-resorptive agent is a highly specific cytokine antagonist comprising REMICADE® infliximab and wherein an effective amount of the anti-resorptive agent remains within the bone for at least one month after administration of the second formulation.
A method of treating osteoporosis in a patient, comprising administering an effective amount of a sustained release formulation comprising an effective amount of a highly specific cytokine antagonist into the cancellous or cortical portion of at least one uncoupled resorbing bone, wherein the highly specific cytokine antagonist comprises REMICADE® infliximab and wherein an effective amount of the highly specific cytokine antagonist remains within the bone for at least one month after administration of the formulation.
A method of treating an osteoporotic patient having a spinal unit comprising an upper vertebral body, a lower vertebral body, and an intervertebral disc therebetween, comprising:
- inserting a sustained release device into at least one vertebral body adjacent to the intervertebral disc, wherein the device is adapted to deliver an effective amount of a bone forming agent and an anti-resorptive agent into the cancellous or cortical portion of the vertebral body, and the anti-resorptive agent comprises REMICADE® infliximab and wherein an effective amount of the bone forming agent and anti-resorptive agent remains within the bone for at least one month after administration.
A method of therapeutically treating an uncoupled resorbing bone in a patient, comprising administering an effective amount of a sustained release formulation comprising an anti-resorptive agent into the cancellous or cortical portion of the uncoupled resorbing bone, wherein the bone is nontumorous and wherein the anti-resorptive agent is a highly specific cytokine antagonist comprising REMICADE® infliximab and wherein an effective amount of the anti-resorptive agent remains within the bone for at least one month after administration of the formulation.
A method of therapeutically treating an uncoupled resorbing bone in a patient, comprising the steps of:
- a) administering an effective amount of a first formulation comprising a bone forming agent into the cancellous or cortical portion of the uncoupled resorbing bone, and
- b) administering an effective amount of a second formulation comprising an anti-resorptive agent in a sustained release form into the cancellous or cortical portion of the uncoupled resorbing bone, wherein the anti-resorptive agent is a highly specific cytokine antagonist comprising REMICADE® infliximab, wherein the second formulation remains in the bone in an effective amount for at least one month.
Dependencies are inferred from the claim text.